PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
तुलना करने के लिए मीट्रिक्स | PEPG | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधPEPGपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −3.8x | −4.1x | −0.6x | |
PEG अनुपात | −0.79 | 0.16 | 0.00 | |
क़ीमत/बुक | 2.2x | 3.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 9.4x | 3.4x | |
अपसाइड (विश्लेषक लक्ष्य) | 85.2% | 100.6% | 44.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 9.3% | 6.6% | अनलॉक करें |